Ryan D. Maynard was named Chief Financial Officer of Foghorn Therapeutics Inc. As of November 14, 2026, Foghorn Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on February 23, 2026, naming 2 appointments (Form 8-K, February 23, 2026).
29 companies changed executives this week, 1 had other signals.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| ONITY GROUP INC. | announced the departure of its Chief Investment Officer | |
| Adicet Bio, Inc. | announced the departure of its Director | |
| MAMMOTH ENERGY SERVICES, INC. | announced the departure of its Chief Operating Officer | |
| CERENOME, INC. | named a new Director | |
| Cohen & Co Inc. | named a new Chief Executive Officer |
Sell to companies like Foghorn Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Foghorn Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-02-23. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Foghorn Therapeutics Inc. files it.
Layoffs on record: about 65 jobs, latest 2026-10-01 (layoff filings and notices).
Also on the record for Foghorn Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 5, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 14.3% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by BVF PARTNERS L P/IL | 9.99% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Deerfield Mgmt, L.P. | 8.64% of the class | 5%+ stakes | Source |
| May 6, 2026 | Stake report, Schedule 13G/A, by FMR LLC | 11.6% of the class | 5%+ stakes | Source |
| January 13, 2026 | Stake report, Schedule 13D/A, by Flagship Ventures Fund V, L.P. | 27.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Foghorn Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Foghorn Therapeutics Inc. and the records around it.
Foghorn Therapeutics Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Deerfield Mgmt, L.P. also filed stake reports on 19 other companies: BridgeBio Oncology Therapeutics, Inc. (Nov 2026), Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026)
- BIOTECHNOLOGY VALUE FUND L P also filed stake reports on 55 other companies: Frazier Life Sciences Acquisition Corp. II (Oct 2026), Olema Pharmaceuticals, Inc. (Oct 2026), Stoke Therapeutics, Inc. (Sep 2026)
- FMR LLC also filed stake reports on 762 other companies: ASPEN NEUROSCIENCE INC (Nov 2026), AVALO THERAPEUTICS INC (Nov 2026), BRAZE INC (Nov 2026)
Watch Foghorn Therapeutics Inc.
Get an email when Foghorn Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Foghorn Therapeutics Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Foghorn Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Foghorn Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-02-23 | In | Chief Financial Officer | 8-K, 2026-02-23 | ||
| 2026-02-23 | In | 8-K, 2026-02-23 |
Who leads Foghorn Therapeutics Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: Ryan D. Maynard, appointed (filed 2026-02-23).
New leaders reset buying decisions — get the Full Report on Foghorn Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Foghorn Therapeutics Inc., with the record behind each one.
Find candidates like Chief Financial Officer at Foghorn Therapeutics Inc.Every change, in the filing's words
Appointed: Ryan D. Maynard, Chief Financial Officer
On February 23, 2026, Foghorn Therapeutics Inc. (the "Company") announced that Ryan D. Maynard had been appointed to serve as the Company's Chief Financial Officer, effective immediately.
Appointed: Ryan D. Maynard
In connection with his appointment, Mr. Maynard will serve as the Company's principal financial officer and principal accounting officer.
- Mr. Maynard, age 56, previously served as Chief Financial Officer of Cara Therapeutics, Inc., a publicly-traded commercial-stage biopharmaceutical company, from September 2022 to 2025.
- Prior to that role he served as the Chief Financial Officer of Paulus Holdings Ltd. d/b/a LetsGetChecked, a global healthcare solutions company, from October 2019 to March 2022, as the Chief Financial Officer of Blade Therapeutics, Inc., a privately held biotechnology company, from February 2018 to June 2019, and as Chief Financial Officer of Rigel Pharmaceuticals, Inc, a public biotechnology company, from 2001 to 2017.
- Mr. Maynard started his career at Ernst and Young LLP., where he earned his CPA.
- He holds a B.S. in Commerce-Accounting from Santa Clara University.
- In connection with his appointment as Chief Financial Officer, Mr. Maynard and the Company entered into a letter agreement that sets forth the terms and conditions of his employment (the "Employment Agreement").
- The Employment Agreement provides for (i) an annual base salary of $510,000, (ii) eligibility to receive an annual performance bonus targeted at 40% of his annual base salary, (iii) a signing bonus of $90,000, (iv) an option award granted under the Company's 2020 Equity Incentive Plan to purchase 400,000 shares of common stock of the Company, to be granted on or after February 23, 2026.
Tools for this story
Each opens in a new tab, filled in for Foghorn Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.
